Top Markets
Coin of the day
GH Research PLC GH Research PLC

GH Research PLC

GHRS
Clasificación en acciones #6594
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to... GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
Precio por acción
$28.53
Última sincronización: 2026-08-27
Capitalización bursátil
$1.96B
Cambio (1 día)
-1.65%
Cambio (1 año)
106.14%
País
IE
Comercio GH Research PLC (GHRS)

Categoría

Ratio P/B de GH Research PLC (GHRS)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de GH Research PLC, el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de GH Research PLC desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH